R-Opra launches full-cycle production of AbbVie's paricalcitol generic Dekalpar for chronic kidney disease in Moscow
核心洞察
R-Opra (搜索), part of the R-Pharm (搜索) group, has begun producing Dekalpar (搜索) (paricalcitol) as a sterile intravenous solution at the Technopolis Moscow special economic zone for treating severe chronic kidney disease (搜索).
The full-cycle manufacturing process spans active pharmaceutical ingredient synthesis through finished drug product, with all stages localized in Russia to reduce import dependence.
Three guaranteed-sales contracts have been signed with the Moscow Department of Investment and Industrial Policy to supply the capital's healthcare system with drugs not previously produced in Russia.
R-Opra (搜索), part of the R-Pharm (搜索) group, has started producing Dekalpar (搜索) (paricalcitol) for treating severe chronic kidney disease (搜索) at the Technopolis Moscow special economic zone. The drug is now available as a sterile intravenous solution, expanding its clinical applications. In 2025, the company had already launched the drug in gelatin capsule form.
The Moscow Department of Investment and Industrial Policy said that three guaranteed-sales contracts have been signed with R-Opra (搜索) to supply the capital's healthcare system. Under these agreements, the city will receive drugs that were not previously produced in Russia.
Clinical Role of Paricalcitol
Paricalcitol is a synthetic analogue of the active form of vitamin D and is used to maintain calcium and phosphorus balance in patients with chronic kidney failure at all stages of the disease. The new intravenous formulation is especially important for dialysis patients, who require parenteral administration of the agent.
Full-Cycle Localized Manufacturing
Production is organised as a full-cycle process, from active pharmaceutical ingredient synthesis to finished drug product. All stages are localised at the group's facilities in Russia, ensuring uninterrupted supply and reducing import dependence.
Market Context and Originator
The original paricalcitol is supplied by AbbVie (搜索), which markets it under the brand name Zemplar. The originator product was registered in the United States in 1998 and in Russia in 2009. The drug is on the list of vital and essential medicines.
According to the state medicines registry, as of April 2026, paricalcitol from Pharmasyntez-Tyumen (搜索) is also available on the Russian market alongside R-Opra (搜索) and AbbVie (搜索).